Literature DB >> 28787335

Increased Circulating CD4+CD25+CD127low/neg Regulatory T-cells as a Prognostic Biomarker in Acute Pancreatitis.

Georgi A Minkov1, Yovcho P Yovtchev, Krasimira S Halacheva.   

Abstract

OBJECTIVE: Early detection of severe forms with unfavorable outcome is the cornerstone that could provide reduction of morbidity and mortality in acute pancreatitis (AP).
METHODS: The percentage of circulating CD4CD25CD127 regulatory T-cells (Tregs) was determined at admission, on the 48th hour, and on the fifth day in 72 patients with AP. We divided patients in 2 groups-Sev1, which includes 19 patients (26.4%) with moderate AP and 39 patients (54.2%) with mild disease, and Sev2, which includes 14 patients (19.4%) with severe AP. Seven patients (9.7%) developed septic complications. The mortality in our group was 9.7%.
RESULTS: The patients in Sev2 had higher percentage of Tregs at admission and on the fifth day compared with patients in Sev1 (P = 0.007 and P = 0.033, respectively). There was no significant difference in percentage of Tregs at admission, on the 48th hour, and on the fifth day in patients who developed and did not develop infected necrosis (P = 0.50, P = 0.72, and P = 0.92, respectively). Patients with poor outcome had elevated percentage of Tregs on the fifth day (P = 0.045).
CONCLUSIONS: The percentage of circulating Tregs may be implicated in the development of early immune suppression in AP. Elevated percentage of circulating Tregs at admission in AP is an independent prognostic biomarker for severe disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28787335     DOI: 10.1097/MPA.0000000000000894

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.

Authors:  Lu Ke; Jing Zhou; Wenjian Mao; Tao Chen; Yin Zhu; Xinting Pan; Hong Mei; Vikesh Singh; James Buxbaum; Gordon Doig; Chengjian He; Weili Gu; Weihua Lu; Shumin Tu; Haibin Ni; Guoxiu Zhang; Xiangyang Zhao; Junli Sun; Weiwei Chen; Jingchun Song; Min Shao; Jianfeng Tu; Liang Xia; Wenhua He; Qingyun Zhu; Kang Li; Hongyi Yao; Jingyi Wu; Long Fu; Wendi Jiang; He Zhang; Jiajia Lin; Baiqiang Li; Zhihui Tong; John Windsor; Yuxiu Liu; Weiqin Li
Journal:  Intensive Care Med       Date:  2022-06-17       Impact factor: 41.787

2.  Emodin Alleviates Intestinal Barrier Dysfunction by Inhibiting Apoptosis and Regulating the Immune Response in Severe Acute Pancreatitis.

Authors:  Qi Zhou; Hong Xiang; Han Liu; Bing Qi; Xueying Shi; Wenhui Guo; Jiacheng Zou; Xueting Wan; Wenjing Wu; Zhengpeng Wang; Wenhui Liu; Shilin Xia; Dong Shang
Journal:  Pancreas       Date:  2021-09-01       Impact factor: 3.327

3.  Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis.

Authors:  Chenchen Yang; Fanchao Dai; Rexiti Pulati; Yan Jiao; Qian Xu
Journal:  J Trop Med       Date:  2022-08-05

4.  Free Total Rhubarb Anthraquinones Protect Intestinal Injury via Regulation of the Intestinal Immune Response in a Rat Model of Severe Acute Pancreatitis.

Authors:  Yuxia Xiong; Li Chen; Ling Fan; Lulu Wang; Yejiang Zhou; Dalian Qin; Qin Sun; Jianming Wu; Shousong Cao
Journal:  Front Pharmacol       Date:  2018-02-13       Impact factor: 5.810

Review 5.  Circulating Lymphocyte Subsets Induce Secondary Infection in Acute Pancreatitis.

Authors:  Lili Ding; Yimin Yang; Hongxiang Li; Haijiao Wang; Pujun Gao
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

Review 6.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

7.  Thymosin alpha 1 in the prevention of infected pancreatic necrosis following acute necrotising pancreatitis (TRACE trial): protocol of a multicentre, randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Jing Zhou; Wenjian Mao; Lu Ke; Tao Chen; Wenhua He; Xinting Pan; Miao Chen; Chengjian He; Weili Gu; Jingyi Wu; Jingchun Song; Haibin Ni; Jianfeng Tu; Junli Sun; Guoxiu Zhang; Weiwei Chen; Bing Xue; Xiangyang Zhao; Min Shao; Yuxiu Liu; Zhihui Tong; Weiqin Li
Journal:  BMJ Open       Date:  2020-09-29       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.